دورية أكاديمية
أعرض في EDS

Dissociable effects of cocaine-seeking behavior following D1 receptor activation and blockade within the caudal and rostral basolateral amygdala in rats.

التفاصيل البيبلوغرافية
العنوان: Dissociable effects of cocaine-seeking behavior following D1 receptor activation and blockade within the caudal and rostral basolateral amygdala in rats.
المؤلفون: Mashhoon Y; Laboratory of Behavioral Neuroscience, Department of Psychology, Boston University, Boston, MA, USA., Tsikitas LA, Kantak KM
المصدر: The European journal of neuroscience [Eur J Neurosci] 2009 Apr; Vol. 29 (8), pp. 1641-53.
نوع المنشور: Journal Article; Research Support, N.I.H., Extramural
اللغة: English
بيانات الدورية: Publisher: Wiley-Blackwell Country of Publication: France NLM ID: 8918110 Publication Model: Print Cited Medium: Internet ISSN: 1460-9568 (Electronic) Linking ISSN: 0953816X NLM ISO Abbreviation: Eur J Neurosci Subsets: MEDLINE
أسماء مطبوعة: Publication: : Oxford : Wiley-Blackwell
Original Publication: Oxford, UK : Published on behalf of the European Neuroscience Association by Oxford University Press, c1989-
مواضيع طبية MeSH: Amygdala*/anatomy & histology , Amygdala*/drug effects , Amygdala*/metabolism , Behavior, Addictive*, Cocaine/*pharmacology , Dopamine Uptake Inhibitors/*pharmacology , Receptors, Dopamine D1/*metabolism, Animals ; Behavior, Animal/drug effects ; Behavior, Animal/physiology ; Benzazepines/pharmacology ; Cocaine-Related Disorders/physiopathology ; Conditioning, Psychological ; Dopamine Agonists/pharmacology ; Dopamine Antagonists/pharmacology ; Male ; Rats ; Rats, Wistar
مستخلص: Research with dopamine D(1) receptor antagonists or neuronal inactivating agents suggests that there is dissociable regulation of cocaine-seeking behavior by the rostral and caudal basolateral amygdala. In the present study, discrete infusions of the D(1) receptor agonist SKF 81297 (0.0-0.8 microg per side) were compared with those of the D(1) receptor antagonist SCH 23390 (0.0-2.0 microg per side) to demonstrate directly the importance of D(1) receptor mechanisms within the rostral and caudal basolateral amygdala for their functional heterogeneity in regulating cocaine-seeking behavior. Under a second-order schedule, cocaine-seeking behavior was studied during maintenance (cocaine and cocaine cues present) and reinstatement (only cocaine cues present). Food-maintained responding was used to examine the specificity of maximal behaviorally effective doses of SKF 81297 and SCH 23390. The results demonstrated that the D(1) agonist (0.4 or 0.8 microg) increased and the D(1) antagonist (1.0 microg) decreased cocaine-seeking behavior during maintenance when infused into the caudal but not the rostral basolateral amygdala. Cocaine intake was not affected by the agonist, and was decreased by the antagonist. During reinstatement, the D(1) agonist (0.4 microg) increased and the D(1) antagonist (1.0 microg) decreased cocaine-seeking behavior when infused into the rostral but not the caudal basolateral amygdala. In tests for behavioral specificity, the above effective doses of SKF 81297 and SCH 23390 used in self-administration experiments did not alter food-maintained responding. However, the 2.0-microg dose of SCH 23390 suppressed drug-maintained and food-maintained responding after infusion into both subregions. Collectively, these findings indicate dissociable sensitivity to D(1) receptor ligands within the caudal and rostral basolateral amygdala for altering cocaine-seeking behavior under different conditions that model phases of addiction.
References: J Subst Abuse Treat. 1989;6(2):95-106. (PMID: 2746717)
J Neurosci. 1999 Mar 15;19(6):2401-11. (PMID: 10066290)
J Neurosci. 2004 Aug 11;24(32):7167-73. (PMID: 15306650)
Behav Brain Res. 1997 Sep;87(2):139-48. (PMID: 9331482)
J Neurosci. 2002 Feb 1;22(3):1126-36. (PMID: 11826141)
Proc Natl Acad Sci U S A. 2000 Apr 11;97(8):4321-6. (PMID: 10760299)
Neuroscience. 1994 Jan;58(2):389-97. (PMID: 8152545)
Eur J Neurosci. 2006 Jan;23(1):219-28. (PMID: 16420431)
Brain Res. 1995 Sep 18;692(1-2):47-56. (PMID: 8548319)
J Neurosci. 2000 Mar 15;20(6):2369-82. (PMID: 10704511)
Brain Res Rev. 2007 Nov;56(1):27-78. (PMID: 17574681)
Psychopharmacology (Berl). 1996 Oct;127(3):213-24. (PMID: 8912399)
Nat Neurosci. 2005 Nov;8(11):1481-9. (PMID: 16251991)
Am J Psychiatry. 1999 Jan;156(1):11-8. (PMID: 9892292)
Neuropsychopharmacology. 2006 Feb;31(2):363-74. (PMID: 15957007)
Eur J Neurosci. 2006 Dec;24(11):3285-98. (PMID: 17156389)
Pharmacol Biochem Behav. 1999 Oct;64(2):327-36. (PMID: 10515309)
Psychopharmacology (Berl). 2004 Nov;176(3-4):459-65. (PMID: 15138757)
J Comp Neurol. 1989 Dec 8;290(2):213-42. (PMID: 2592611)
Ann N Y Acad Sci. 2007 Dec;1121:576-97. (PMID: 17846151)
Brain Res Brain Res Rev. 2001 Oct;36(2-3):129-38. (PMID: 11690609)
Neurobiol Learn Mem. 2005 Mar;83(2):93-103. (PMID: 15721792)
Neurosci Lett. 1998 Jun 12;249(1):49-52. (PMID: 9672386)
Neuropsychopharmacology. 2003 Oct;28(10):1721-9. (PMID: 12865896)
Neuroscience. 2003;121(3):747-57. (PMID: 14568033)
Ann N Y Acad Sci. 2007 May;1104:192-212. (PMID: 17416920)
Psychopharmacology (Berl). 2001 Mar;154(3):301-10. (PMID: 11351937)
Psychopharmacology (Berl). 2003 Jul;168(1-2):3-20. (PMID: 12402102)
J Neurosci. 2005 Sep 21;25(38):8665-70. (PMID: 16177034)
Psychopharmacology (Berl). 2005 Nov;183(1):41-53. (PMID: 16163523)
J Pharmacol Exp Ther. 1981 Jul;218(1):271-81. (PMID: 7241384)
Psychopharmacology (Berl). 2007 Oct;194(3):321-31. (PMID: 17589830)
J Neurosci. 2001 Jul 15;21(14):RC155. (PMID: 11425882)
Psychopharmacology (Berl). 2004 Jul;174(2):237-45. (PMID: 14726992)
Neuroscience. 2006;137(2):699-706. (PMID: 16289883)
Psychopharmacology (Berl). 2003 Jul;168(1-2):57-65. (PMID: 12845418)
Neuroscience. 2007 Jun 8;146(4):1484-94. (PMID: 17449185)
Nat Neurosci. 2004 Apr;7(4):389-97. (PMID: 15034590)
Psychopharmacology (Berl). 2000 Dec;153(1):17-30. (PMID: 11255926)
J Neurosci. 2000 Oct 1;20(19):7489-95. (PMID: 11007908)
Behav Neurosci. 2001 Jun;115(3):589-601. (PMID: 11439448)
Brain Res. 1999 Dec 11;850(1-2):127-35. (PMID: 10629756)
J Neurosci. 2002 Jul 15;22(14):6247-53. (PMID: 12122083)
Prog Neuropsychopharmacol Biol Psychiatry. 2007 Nov 15;31(8):1593-600. (PMID: 17900777)
Proc Natl Acad Sci U S A. 2001 Feb 13;98(4):1976-81. (PMID: 11172061)
J Psychopharmacol. 1998;12(1):54-67. (PMID: 9584969)
معلومات مُعتمدة: R01 DA011716-05 United States DA NIDA NIH HHS; R01 DA011716-06A2 United States DA NIDA NIH HHS; R01 DA011716-10 United States DA NIDA NIH HHS; R01 DA011716-08 United States DA NIDA NIH HHS; R01 DA011716-03 United States DA NIDA NIH HHS; R01 DA011716-04 United States DA NIDA NIH HHS; R01 DA011716 United States DA NIDA NIH HHS; R01 DA011716-02 United States DA NIDA NIH HHS; R01 DA011716-07 United States DA NIDA NIH HHS; R01 DA011716-09 United States DA NIDA NIH HHS
المشرفين على المادة: 0 (Benzazepines)
0 (Dopamine Agonists)
0 (Dopamine Antagonists)
0 (Dopamine Uptake Inhibitors)
0 (Receptors, Dopamine D1)
0 (SCH 23390)
71636-61-8 (SK&F 81297)
I5Y540LHVR (Cocaine)
تواريخ الأحداث: Date Created: 20090508 Date Completed: 20090713 Latest Revision: 20211020
رمز التحديث: 20221213
مُعرف محوري في PubMed: PMC2905154
DOI: 10.1111/j.1460-9568.2009.06705.x
PMID: 19419427
قاعدة البيانات: MEDLINE
الوصف
تدمد:1460-9568
DOI:10.1111/j.1460-9568.2009.06705.x